Avacta Group plc, a life sciences company, is set to host a webinar on April 10, 2024, to discuss the updated clinical data from the first-in-human Phase 1 trial of AVA6000. This drug is the first of the Company's pre|CISION™ peptide drug conjugates that targets chemotherapy to the tumor. The webinar will cover the data to be presented at the 2024 American Association for Cancer Research Annual Meeting. The presentation will include a Q&A session for investors, and questions can be submitted pre-event as part of the registration process.

The webinar will be chaired by news and corporate events presenter Katie Pilbeam and hosted by Turner Pope Investments. Avacta Group plc's Chief Executive Officer, Dr. Alastair Smith, will lead the webinar. The Company's pre|CISION™ platform modifies chemotherapy to be activated only in the tumor tissue, reducing systemic exposure and toxicity. The lead pre|CISION™ programme, AVA6000, has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.

Avacta Group plc is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company has two divisions: an oncology biotech division developing novel, highly targeted cancer drugs and a diagnostics division focused on supporting healthcare professionals and broadening access to testing. Avacta's proprietary platforms, Affimer® and pre|CISION™, underpin its cancer therapeutics, while the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.

Investors and interested parties can register for the webinar through the provided link. For further information, individuals can contact Avacta Group plc directly or visit their website. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply.